Methylation Profile of BRCA1, RASSF1A and ER in Vietnamese Women with Ovarian Cancer

  • Lan, Vo Thi Thuong (Faculty of Biology, VNU University of Science) ;
  • Thuan, Ta Bich (Faculty of Biology, VNU University of Science) ;
  • Thu, Doan Minh (Faculty of Biology, VNU University of Science) ;
  • Uyen, Nguyen Quynh (Institute of Microbiology and Biotechnology, Vietnam National University) ;
  • Ha, Ngo Thi (Institute of Microbiology and Biotechnology, Vietnam National University) ;
  • To, Ta Van (Department of Cytology and Pathology, National Cancer Hospital)
  • Published : 2013.12.31


DNA methylation is considered a promising biomarkers for diagnosis of cancer in general and of ovarian cancer in particular. In our study, we validated the accuracy of methylation specific polymerase chain reaction (MSP) to analyze the methylation pattern of BRCA1, RASSF1A and ER in 59 and 10 Vietnamese patients with epithelial ovarian cancer (EOC) and benign ovarian tumors, respectively. We found methylation of BRCA1, RASSF1A and ER in 11/59 (18.6%), 40/59 (67.8%) and 15/59 (25.4%) of EOC cases, while methylation of BRCA1 was only detected in 2/10 (20%) benign ovarian patients. Forty five out of the 59 EOCs (78%) demonstrated methylation at one or more genes. The methylation frequency of RASSF1A was significantly associated with EOC (p<0.0005). No significant association was observed between methylation status of these genes and the clinical and pathological parameters of tumors collected from Vietnamese women suffering from ovarian cancer.


  1. Barnholtz-Sloan JS, Schwartz AG, Qureshi F (2003). Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol, 189, 1120-7.
  2. Barton CA, Hacker NF, Clark SJ, Philippa M, O'Brien PM (2008). DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol, 109, 129-9.
  3. BonDurant AE, Huang Z, Whitaker RS, et al (2011). Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol, 123, 581-7.
  4. Clark SJ, Harrison J, Paul CL, Frommer M (1994). High sensitivity mapping of methylated cytosines. Nucleic Acids Res, 22, 2990-7.
  5. de Caceres I, Battagli C, Esteller M, et al (2004). Tumor cellspecific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res, 64, 6476-1.
  6. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S (2008). Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer, 18, 660-9.
  7. Esteller M, Silva JM, Dominguez G, et al (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst, 92, 564-70.
  8. Esteller M, Corn PG, Baylin SB, Herman JG (2001). A gene hypermethylation profile of human cancer. Cancer Res, 61, 3225-9.
  9. Feng S, Rubbi L, Jacobsen SE, Pellegrini M (2011). Determining DNA methylation profiles using sequencing. Methods Mol Biol, 733, 223-8.
  10. Heichman KA, Warren JD (2012). DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med, 50, 1707-1.
  11. Heyn H, Esteller M (2012). DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet, 13, 679-3.
  12. Houshdaran S, Hawley S, Palmer C, et al (2010). DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE, 5, 9359.
  13. Kristensen LS, Hansen L (2009). PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem, 55, 1471-3.
  14. Agathanggelou A, Honorio S, Macartney DP, et al (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509-8.
  15. Asadollahi R, Hyde AC, Zhong XY (2010). Epigenetics of ovarian cancer: From the lab to the clinic. Gynecol Oncol, 118, 81-7.
  16. Lapidus RG, Nass SJ, Butash KA, et al (1998). Mapping of ER gene CpG island methylation by methylation-specific polymerase chain reaction. Cancer Res, 58, 2515-9.
  17. Liu L, Yoon JH, Dammann R, Pfeifer GP (2002). Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogen, 21, 6835-1.
  18. Mann M, Cortez V, Vadlamudi RK (2011). Epigenetics of estrogen receptor signaling: Role in hormonal cancer progression and therapy. Cancers, 3, 1691-7.
  19. Mehrotra J, Ganpat MM, Kanan Y, et al (2004). Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res, 10, 2052-7.
  20. Montavon C, Gloss BS, Warton K, et al (2012). Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol, 124, 582-8.
  21. Matoo AA, Khan H, Wani HA, et al (2013). RAS association domain isoform A gene (RASSF1A) hypermethylation in ovarian cancer patients of Kashmir Valley. J Pakistan Med Students, 3, 87-3.
  22. Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N (2012). Methylation of tumor suppressor genes in ovarian cancer. Experimental and Therapeutic Medicine, 4, 1092-6.
  23. Pan YM, Wu YZ, Shi YF, Zhu XQ (2010). Methylation of tumor suppressor gene RASSF1A and BRCA1 in primary epithelial ovarian cancer. Sci Res and Essays, 5, 3939-4.
  24. Pathy NB, Hartman M, Yip CH, et al (2012). Ethnic differences in survival after breast cancer in South East Asia. PLoS ONE, 7, 30995.
  25. Rathi A, Virmani AK, Schorge JO, et al (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res, 8, 3324-1.
  26. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-9.
  27. Teodoridis JM, Hall J, Marsh S, et al (2005). CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res, 65, 8961-7.
  28. Widschwendter M, Jones A, Teschendorff AE (2013). Epigenetics makes its mark on women-specific cancers-an opportunity to redefine oncological approaches? Gynecol Oncol, 128, 134-3.
  29. Wiencke JK (2004). Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer, 4, 79-4.
  30. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA (2005). High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogen, 159, 114-2.
  31. Wiley A, Katsaros D, Chen H, et al (2006). Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovariantumors with low malignant potential. Cancer, 107, 299-8.
  32. Zhang Q, Hu G, Yang Q, et al (2013). A multiplex methylationspecific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol, 130, 132-9.

Cited by

  1. No Association between BRCA1 Immunohistochemical Expression and Tumor Grade, Stage or Overall Survival in Platinum-Treated Epithelial Ovarian Cancer Patients vol.15, pp.10, 2014,
  2. Methylation of RASSF1A and CDH13 Genes in Individualized Chemotherapy for Patients with Non-small Cell Lung Cancer vol.15, pp.12, 2014,
  3. Combined Effects Methylation of FHIT, RASSF1A and RARβ Genes on Non-Small Cell Lung Cancer in the Chinese Population vol.15, pp.13, 2014,
  4. C13orf18 and C1orf166 (MULAN) DNA Genes Methylation are Not Associated with Cervical Cancer and Precancerous Lesions of Human Papillomavirus Genotypes in Iranian Women vol.15, pp.16, 2014,
  5. Association between RASSF1A Ala133Ser Polymorphism and Cancer Susceptibility: A Meta-Analysis Involving 8,892 Subjects vol.15, pp.8, 2014,
  6. Association between Ras association domain family 1A Promoter Methylation and Esophageal Squamous Cell Carcinoma: a Meta-analysis vol.15, pp.9, 2014,
  7. Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma vol.13, pp.1, 2015,
  8. A methylation-specific dot blot assay for improving specificity and sensitivity of methylation-specific PCR on DNA methylation analysis vol.20, pp.4, 2015,
  9. FOXD3 may be a new cellular target biomarker as a hypermethylation gene in human ovarian cancer vol.19, pp.1, 2019,